Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LIM homeobox protein 6 is a transcription factor belonging to the LIM homeobox domain family, containing two LIM domains and a central homeodomain for DNA binding. In humans, it plays a critical regulatory role during embryogenesis for neural and lymphoid cell differentiation. LHX6 suppresses tumorigenesis by promoting cell cycle arrest and apoptosis and limiting cell proliferation and migration. In lung and cervical cancer, its expression is frequently silenced through promoter hypermethylation, and restoration of LHX6 expression inhibits tumor cell growth both in vitro and in vivo. Downregulation or loss of LHX6 results in increased cell proliferation, reduced apoptosis, and deregulation of several cell cycle and growth-related genes. Its methylation status is being investigated as a potential biomarker for early diagnosis of certain cancers.
Epigenetic reactivation (e.g., demethylating agents restore expression); Indirect modulation of apoptosis, cell cycle, and proliferation genes (e.g., upregulating p53, p21; downregulating Bcl-2, cyclinD1, c-myc, CD44, MMP7)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on LIM homeobox protein 6 (LHX6).